T. Rowe Price reports 10.1% stake in Bicara Therapeutics
Rhea-AI Filing Summary
BICARA THERAPEUTICS INC ownership update: T. Rowe Price Investment Management, Inc. reports beneficial ownership of 6,605,780 shares of common stock, representing 10.1% of the class as disclosed in an amended Schedule 13G/A. The filing states T. Rowe Price "hereby declares and affirms that the filing of shall not be construed as an admission that Price Investment Management is the beneficial owner," denying beneficial ownership. The report lists 6,597,481 shares as sole voting power and 6,605,780 shares as sole dispositive power. The filing is signed by Ellen York, Vice President, dated 04/08/2026.
Positive
- None.
Negative
- None.
Insights
T. Rowe Price reports a 10.1% position while disclaiming beneficial ownership.
The amendment lists 6,605,780 shares and a 10.1% stake as the reported position. The filing records sole voting and dispositive power in nearly identical counts, indicating control over voting and disposition for the reported shares.
Because the filing includes an explicit denial of beneficial ownership, the practical effect depends on underlying client or fiduciary relationships; subsequent filings or disclosures may clarify economic interest.
Key Figures
Key Terms
Schedule 13G/A regulatory
Beneficial ownership financial
Sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Schedule 13G/A from T. Rowe Price (BCAX) report?
How much voting power does T. Rowe Price report for BCAX?
When was the Schedule 13G/A signed and by whom?
AI-generated analysis. How Rhea-AI works. Not financial advice.